Login / Signup

Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies.

Andrew J BishopJace P LandryChristina L RolandRavin RatanBarry W FeigBryan S MoonMaria A ZarzourWei-Lien WangAlexander J LazarValerae O LewisKeila E TorresB Ashleigh Guadagnolo
Published in: Cancer (2020)
Local therapy provides durable tumor control in the majority of patients with DTs. However, young patients, patients with an extremity location, and patients with large tumors are at increased risk of recurrence. When active treatment is indicated, systemic therapy should perhaps be considered as a first-line option in these high-risk subsets. Prospective multi-institutional studies evaluating this strategy are warranted.
Keyphrases
  • end stage renal disease
  • chronic kidney disease
  • ejection fraction
  • stem cells
  • peritoneal dialysis
  • peripheral blood
  • mesenchymal stem cells
  • cell therapy
  • case control
  • patient reported
  • free survival